Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Quentin M. Anstee, Alessandro Mantovani, Herbert Tilg, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 7, pp. 425-439
Closed Access | Times Cited: 258

Showing 26-50 of 258 citing articles:

Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications
Csaba Mátyás, György Haskó, Lucas Liaudet, et al.
Nature Reviews Cardiology (2020) Vol. 18, Iss. 2, pp. 117-135
Closed Access | Times Cited: 100
A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease
Jonathan Zhi Kai Toh, Xin‐Hui Pan, Phoebe Wen Lin Tay, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 11, pp. 2462-2473.e10
Closed Access | Times Cited: 92
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne, Giovanni Targher
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 28-43
Open Access | Times Cited: 78
Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia
Ze Chen, Jiayi Liu, Feng Zhou, et al.
Circulation Research (2021) Vol. 128, Iss. 11, pp. 1747-1765
Open Access | Times Cited: 75
NAFLD in the Elderly
Saleh A. Alqahtani, Jörn M. Schattenberg
Clinical Interventions in Aging (2021) Vol. Volume 16, pp. 1633-1649
Open Access | Times Cited: 66
Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, et al.
Gut (2022) Vol. 72, Iss. 2, pp. 372-380
Open Access | Times Cited: 65
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
David Niederseer, Bernhard Wernly, Elmar Aigner, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 467-467
Open Access | Times Cited: 58
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Gabriel Tayguara Silveira Guerreiro, Larisse Longo, Mariana Fonseca, et al.
Hepatology International (2021) Vol. 15, Iss. 2, pp. 380-391
Closed Access | Times Cited: 58
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Anna Martin, Sonja Lang, Tobias Goeser, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 533-546
Open Access | Times Cited: 48
Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies
Francesco Bellinato, Paolo Gisondi, Alessandro Mantovani, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 7, pp. 1277-1288
Open Access | Times Cited: 40
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
Gashaw Hassen, Abhishek Singh, Gizeshwork Belete, et al.
Cureus (2022)
Open Access | Times Cited: 39
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Piero Portincasa
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 993-1006
Open Access | Times Cited: 26
The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
Theresa Hydes, Oliver John Kennedy, Ryan Buchanan, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 25
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeong Jun Song
Nutrients (2023) Vol. 15, Iss. 18, pp. 3970-3970
Open Access | Times Cited: 22
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
Mary E. Rinella, James F. Trotter, Manal F. Abdelmalek, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 4, pp. 735-744
Open Access | Times Cited: 73
Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis
Karn Wijarnpreecha, Susan Lou, Panadeekarn Panjawatanan, et al.
Digestive and Liver Disease (2018) Vol. 50, Iss. 11, pp. 1166-1175
Closed Access | Times Cited: 68
Cardiolipotoxicity, Inflammation, and Arrhythmias: Role for Interleukin-6 Molecular Mechanisms
Alessandra Alì, Mohamed Boutjdir, Ademuyiwa S. Aromolaran
Frontiers in Physiology (2019) Vol. 9
Open Access | Times Cited: 67
Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
Alessandro Mantovani, Teresa Turino, Maria Giovanna Lando, et al.
Diabetes & Metabolism (2019) Vol. 46, Iss. 4, pp. 296-303
Open Access | Times Cited: 63
Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation
Xiaoyan Cai, Sulin Zheng, Ying Liu, et al.
Liver International (2020) Vol. 40, Iss. 7, pp. 1594-1600
Closed Access | Times Cited: 61
Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review
Rosa Lombardi, Silvia Fargion, Anna Ludovica Fracanzani
Digestive and Liver Disease (2019) Vol. 51, Iss. 9, pp. 1214-1222
Closed Access | Times Cited: 57
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review
Stefano Ballestri, Mariano Capitelli, Maria Cristina Fontana, et al.
Advances in Therapy (2020) Vol. 37, Iss. 5, pp. 1910-1932
Open Access | Times Cited: 54
Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
Huapeng Lin, Xinrong Zhang, Guanlin Li, et al.
Journal of Clinical and Translational Hepatology (2021) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 46
The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis
Shanshan Liu, Jialu Wang, Shujing Wu, et al.
Metabolism (2021) Vol. 120, pp. 154779-154779
Closed Access | Times Cited: 41
Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
Alessandro Mantovani, Andrea Dalbeni, Giorgia Beatrice, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 968-968
Open Access | Times Cited: 28

Scroll to top